Neoplasms Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 26, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Neoplasms. It connects disease background, epidemiology, target mechanism, competition, transactions, unmet need and market attractiveness.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Executive assessment

Neoplasms receives a directional score of 53/100, combining unmet need (48/100), competitive intensity (96/100) and market attractiveness (95/100). It is a prioritization framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

The reproducible record is Patsnap disease ID 62eaee6d9ee44410b8aca59dfc7408e9 and MeSH identifier D009369. Stable identifiers prevent historical names, gene-defined subtypes and overlapping syndromic labels from producing inconsistent landscapes.

A target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, setting, safety and endpoint. An overly broad population can inflate market size while weakening biological signal and recruitment. The first population should be biologically coherent and operationally feasible.

Map the pathway from symptom recognition through specialist referral, testing, treatment and monitoring. Diagnostic delay, center concentration and testing access can constrain trials and commercialization as much as drug performance.

Epidemiology and disease burden

Epidemiology evidence 1: 中美两国恶性肿瘤疾病负担、流行趋势及归因风险因素比较

【Key words】 Neoplasms; Incidence; Mortality; Epidemic trends; 5-year survival rate; Attributable risk Fund programs: National Key Research and Development Program of China (2021YFC2500400); Tianjin Health Committee Foundation (TJWJ2021MS008);Tianjin Key Medical Discipline (Specialty) Construction Project (TYXZDXK-009A) 数 ［3］。世界各国发布的肿瘤负担原始数据由世界 卫生组织下属的国际癌症研究机构（International Agency for Research on Cancer， IARC）根据统一标 准汇总和测算，形成GLOBOCAN 数据库，呈现全球 185 个国家或地区的36 种恶性肿瘤疾病负担的估 计结果，为世界范围内的癌谱比较提供数据支持。 2024 年2 月，GLOBOCAN 2022 数据库正式发布，中 国同步发布最新恶性肿瘤统计报告 ［4-5］。本研究主 要基于GLOBOCAN 数据库及肿瘤归因风险既往研 究，详细描述和比较了中美两国恶性肿瘤最新疾病 恶性肿瘤是影响居民健康的重大公共卫生问 题，也是影响全球疾病负担的关键因素 ［1］。世界卫 生组织数据显示，恶性肿瘤是导致居民过早死亡的 主要原因，在大多数国家表现为第1 或第2 大死 因 ［2-3］。我国的肿瘤登记工作已经覆盖全国所有县 区，国家癌症中心承担数据收集、汇总、质控等工 作，并经国家卫生主管部门审核后发布。美国癌症 协会每年利用美国国家癌症研究所、北美中央癌症 登记协会和国家卫生统计中心提供的恶性肿瘤相 关数据，预测美国当年恶性肿瘤发病和死亡例 负担、流行趋势、5 年相对生存率及归因风险因素， 并进一步讨论了两国主要肿瘤防控措施，以期为我 国肿瘤防控策略制定提供理论参考。 资料与方法 一、数据来源

Review source

Epidemiology evidence 2: Global Cancer Statistics, 2002

For the last 30 years, the International Agency for Research on Cancer has prepared estimates of the global cancer burden. Beginning in 1975 with broad estimates of numbers of new cases for 12 common types of cancer in different areas of the world,1 we were able to provide detailed country-specific estimates of incidence, mortality, and prevalence, by sex and age group for 26 types of cancer in the year 2000.2 The latter set of estimates3 has recently been updated using newer sources of data and improved methods of estimation to prepare global estimates for the year 2002.4 As before, the emphasis is on three measures of the burden of cancer worldwide: incidence, mortality, and prevalence. Incidence is the number of new cases occurring, expressed as an absolute number of cases per year or as a rate per 100,000 persons per year. The latter approximates the average risk of developing a cancer in one year and is used for comparisons between countries or world areas, or within populations over time. Primary prevention strategies aim to reduce incidence, although increasing incidence does not necessarily reflect failure in primary prevention. The introduction of programs for early detection results in a temporary increase in incidence as subclinical cancer cases are discovered. This increase will be maintained if some of the cases being detected represent “overdiagnosis” (ie, cancers that would otherwise never have been diagnosed in the individual’s life).

Review source

Epidemiology evidence 3: Global Cancer Statistics

Introduction Cancer is the leading cause of death in economically developed countries and the second leading cause of death in developing countries.1 The burden of cancer is increasing in economically developing countries as a result of population aging and growth as well as, increasingly, an adoption of cancer-associated lifestyle choices including smoking, physical inactivity, and ‘‘westernized’’ diets. In this article, we provide an overview of the global cancer burden, including the estimated number of new cancer cases and deaths in 2008 and the incidence and mortality rates by region for selected cancer sites. These statistics are based on GLOBOCAN 2008,2 the standard set of worldwide estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer (IARC) for 2008. We comment on the recent incidence and mortality patterns observed for a number of common cancer forms, alongside established preventive measures that can reduce the worldwide cancer burden. Data Sources and Methods Incidence data (the number of newly diagnosed cases each year) are derived from population-based cancer registries, which may cover entire national populations but more often cover smaller, subnational areas, and, particularly in developing countries, only urban environments, such as major cities. Although the quality of 1Vice President, Surveillance Research, American Cancer Society, Atlanta, GA; 2Deputy Head, Section of Cancer Information, International Agency for Research on Cancer, Lyon, France; 3Epidemiologist, Surveillance Research, American Cancer Soc

Review source

Convert population evidence into a funnel: total affected → diagnosed → clinically eligible → treated → realistically accessible. Incidence, point prevalence and lifetime prevalence are not interchangeable. Do not pool incompatible age bands, case definitions or health systems.

For Neoplasms, quantify diagnostic yield, severity distribution, center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges with a source and access date for every parameter. Market models should show which assumptions drive recruitment and adoption.

A small, well-defined population concentrated in expert centers may be more actionable than a larger population with poor diagnosis. Epidemiology therefore must connect to real patient identification, clinical eligibility and access.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: progression, incomplete control, toxicity, weak durability, burdensome delivery, diagnostic delay or absent options for a subgroup. Disease severity alone does not demonstrate that a program can deliver measurable benefit.

A strong Neoplasms thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit is measurable within a feasible period and whether natural-history variability can be controlled.

Proceed through gates: confirm phenotype and natural history, demonstrate engagement, observe pharmacodynamic response, show interpretable clinical signal and only then scale. Pre-agreed stop criteria protect capital and make negative studies informative.

Target mechanism anchor: p53

Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:35618207, PubMed:36634798, PubMed:38653238, PubMed:9840937). Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17189187, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:38653238, PubMed:9840937). Negatively regulates cell division by controlling expression of a set of genes required for this process (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:9840937). One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression (PubMed:12524540, PubMed:17189187). Its pro-apoptotic activity is activated via its interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 (PubMed:12524540). However, this activity is inhibited when the interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 is displaced by PPP1R13L/iASPP (PubMed:12524540). In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-BMAL1-mediated transcriptional activation of PER2 (PubMed:24051492).

The mechanism anchor is TP53, a testable pathway hypothesis rather than a claim that every patient is target-dependent. Establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and therapeutic window.

Use orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit safety testing. Human evidence should carry more weight than model-only observations. Related failures should be analyzed for exposure, population and endpoint lessons.

A go decision requires a complete chain from relevant biology to achievable modulation, measurable pharmacodynamics and a plausible bridge to clinical benefit. Missing links require targeted experiments, not stronger narrative.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Clinical development and competition

The focused search returned 194828 registered studies.

• JPRN-jRCT2031260435 — Phase II Trial of Zolbetuximab, Durvalumab, and FLOT (5-FU, Leucovorin, Oxaliplatin, and Docetaxel) Combination Neoadjuvant Chemotherapy for CLDN18.2-Positive Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (Zodiac-Neo); 募集中; Phase 2; sponsor Astellas Pharma, Inc.; enrollment 29.
• JPRN-UMIN000062673 — Performance study of the POPLAR system, a diagnostic system for molecular subtype classification of endometrial cancer; 限定募集中/Enrolling by invitation; Not Applicable; sponsor Hokkaido University, Center for Development of Advanced Computing, Hokkaido University Hospital; enrollment 550.
• NCT07783607 — MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma (MM-CARE); Not yet recruiting; Not Applicable; sponsor The University of Vermont Medical Center; enrollment 33.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies for one asset can inflate activity. Normalize records by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact subtype.

Compare against the likely future standard at launch. Whitespace may come from earlier treatment, genotype selection, durability, lower monitoring, safer chronic use or simpler delivery. Differentiation should be visible in protocol design and prospective analyses.

Recruitment risk requires site-density, testing, travel, competing-protocol and screen-failure assumptions. Natural-history evidence can reduce uncertainty but cannot substitute for controlled efficacy evidence when outcomes are variable.

Transactions and partnering attractiveness

The query returned 674 directly matched 2023–2026 transactions.

• 剂泰科技与威斯克生物达成战略合作 (2026-08-21). Review stage, rights, territory, milestones and economics before using it as a comparable.
• IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies (2026-08-20). Review stage, rights, territory, milestones and economics before using it as a comparable.
• HanchorBio and Taiwan Cancer Moonshot Project-NTU Establish Strategic Collaboration to Advance Precision Oncology (2026-08-09). Review stage, rights, territory, milestones and economics before using it as a comparable.

Separate upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope. A defensible comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires disease segmentation, target-validation chain, competition map, clinical plan, intellectual property, manufacturability evidence and a transparent risk-adjusted model. Outreach is strongest around a catalyst that retires material risk.

Low direct deal activity may represent whitespace, but can also signal difficult science or economics. Use broader therapeutic-area transactions only when relevance is explicit; rare-disease deals are not automatically interchangeable.

Market attractiveness and access

Attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, setting, payer controls, alternatives, monitoring and reimbursement. Patient count is only one driver. Reliable identification and meaningful benefit can support a small population; fragmented diagnosis can undermine a larger one.

Build scenarios for diagnosed prevalence, eligible share, timing, competition, net price, persistence and penetration. Keep assumptions traceable and refresh them when new epidemiology, trial or transaction evidence appears.

Begin payer research before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Quality of life, caregiver burden, hospital use and diagnostic costs may be essential to the value case.

Risks, decision gates and recommendation

• Confirm a consistently diagnosed and recruitable population.
• Demonstrate TP53 relevance in the selected phenotype.
• Connect engagement to a biomarker and meaningful endpoint.
• Refresh competition before every investment gate.
• Validate sites, testing, access, pricing and adoption.
• Treat zero-result searches as prompts for broader queries, not proof of absence.

Neoplasms merits continued milestone-based evaluation if a coherent subgroup can be identified, target modulation can be measured and benefit remains differentiated against future care. The current evidence supports targeted diligence rather than unconditional investment.

The business-development objective is a partner-ready thesis covering patient segment, mechanism, whitespace, development path and value-inflection milestones. Evidence gaps should remain visible rather than hidden in a composite score.

Methodology and source note

This report was assembled on August 26, 2026 using Patsnap MCP tools: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and can change as databases update.

Weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease profile, epidemiology coverage, registered trials, development-drug counts and direct transactions. Rerun with synonyms, roll-ups, targets and assets before commitment.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Conclusion

The central question for Neoplasms is whether a biologically grounded therapy can deliver material benefit in an identifiable population and remain differentiated through launch. This evidence provides a starting map; the explicit gaps define the next diligence plan.